Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test a new treatment combination including cadonilimab
and anlotinib in recurrent, metastasis and persistent cervical cancer. The main questions it
aims to answer are:
- The efficacy of this combination in R/M/P CC;
- The tolerance of this combination in R/M/P CC;
- Possible biomarker of treatment response for this combination.
Participants will receive cadonilimab of 10mg/kg every three weeks at day 1 and take
anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break. This treatment will
continue until progression or intolerable toxicity or withdraw of participants and it will
last for no longer than 2 years.
Phase:
Phase 2
Details
Lead Sponsor:
Zhongnan Hospital
Collaborators:
Akeso Biopharma Co., Ltd. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.